Best Practice & Research Clinical Anaesthesiology
Volume 21, Issue 2 , Pages 271-289 , June 2007

Estimating the cost of blood: past, present, and future directions

  • Aryeh Shander, MD, FCCP, FCCM (Chief, Department of Anesthesiology and Critical Care and Hyperbaric Medicine Medical Director, New Jersey Institute for the Advancement of Bloodless Medicine and Surgery)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 201 894 3238; Fax: +1 201 894 0585.

References 

  1. Van Hulst M, De Wolf JT, Staginnus U, et al. Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sanguinis. 2002;83:146–155
  2. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion. 2003;43:721–729
  3. Vamvakas EC. Epidemiology of red blood cell utilization. Transfusion Medicine Reviews. 1996;10:44–61
  4. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts: blood transfusion. The New England Journal of Medicine. 1999;340:438–447
  5. Hannon TJ, Gjerde KP. The contemporary economics of transfusions. In:  Spiess BD,  Spence RK,  Shander A editor. Perioperative transfusion medicine. 2nd edn. Philadelphia: Lippincott Williams & Wilkins; 2006;p. 13–38
  6. Sloand EM, Pitt E, Klein HG. Safety of the blood supply. JAMA: The Journal of the American Medical Association. 1995;274:1368–1373
  7. Brooks JP. Reengineering transfusion and cellular therapy processes hospitalwide: ensuring the safe utilization of blood products. Transfusion. 2005;45(supplement):159S–171S
  8. Blumberg N. Allogeneic transfusion and infection: economic and clinical implications. Seminars in Hematology. 1997;34:34–40
  9. Williamson LM, Lowe S, Love EM, et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. British Medical Journal. 1999;319:16–19
  10. Sazama K, DeChristopher PJ, Dodd R, et al. Practice parameter for the recognition, management, and prevention of adverse consequences of blood transfusion. Archives of Pathology & Laboratory Medicine. 2000;124:61–70
  11. Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Reviews. 2001;15:69–83
  12. Klein HG. Allogeneic transfusion risks in the surgical patient. American Journal of Surgery. 1995;170(supplement 6A):21S–26S
  13. Dodd RY. Adverse consequences of blood transfusion: quantitative risk estimates. In:  Nance ST editors. Blood supply: risks, perceptions and prospects for the future. 1st edn. Bethesda, MD: American Association of Blood Banks; 1994;p. 1–24
  14. Kopko PM, Marshall CS, MacKenzie MR, et al. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA: The Journal of the American Medical Association. 2002;287:1968–1971
  15. Denton TA, Diamond GA, Matloff JM, Gray RJ. Anemia therapy: individual benefit and societal cost. Seminars in Oncology. 1994;21:29–35
  16. Barnett A, Cremieux P-Y, Fendrick AM, et al. Anemia-related costs for cancer patients. Journal of Managed Care Medicne. 2002;6:20–28
  17. Levy MM, Abraham E, Zilberberg M, MacIntyre NR. A descriptive evaluation of transfusion practices in patients receiving mechanical ventilation. Chest. 2005;27:928–935
  18. Rosencher N, Kerkkamp HE, Macheras G, et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion. 2003;43:459–469
  19. Hébert PC, Wells G, Martin C, et al. Variation in red cell transfusion practice in the intensive care unit: a multicentre cohort study. Critical care (London, England). 1999;3:57–63
  20. Capraro L, Nuutinen L, Myllyla G. Transfusion thresholds in common elective surgical procedures in Finland. Vox Sanguinis. 2000;78:96–100
  21. Goodnough LT, Soegiarso RW, Birkmeyer JD, Welch HG. Economic impact of inappropriate blood transfusions in coronary artery bypass graft surgery. The American Journal of Medicine. 1993;94:509–514
  22. Vincent JL, Baron J-F, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA: The Journal of the American Medical Association. 2002;288:1499–1507
  23. Dunne JR, Malone D, Tracy JK, et al. Perioperative anemia: an independent risk factor for infection, mortality, and resource utilization in surgery. The Journal of Surgical Research. 2002;102:237–244
  24. Taylor RW, O'Brien J, Trottier SJ, et al. Red blood cell transfusions and nosocomial infections in critically ill patients. Critical Care Medicine. 2006;34:2302–2309
  25. Zallen G, Offner PJ, Moore EE, et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. American Journal of Surgery. 1999;178:570–572
  26. Moore FA, Moore EE, Sauaia A. Blood transfusion. An independent risk factor for postinjury multiple organ failure. Archives of Surgery. 1997;132:620–624
  27. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT study: anemia and blood transfusion in the critically ill – current clinical practice in the United States. Critical Care Medicine. 2004;32:39–52
  28. Vamvakas EC, Carven JH. Allogeneic blood transfusion, hospital charges, and length of hospitalization: a study of 487 consecutive patients undergoing colorectal cancer resection. Archives of Pathology & Laboratory Medicine. 1998;122:145–151
  29. Forbes JM, Anderson MD, Anderson GF, et al. Blood transfusion costs: a multicenter study. Transfusion. 1991;31:318–323
  30. Mohandas K, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion. 1995;35:427–430
  31. Cantor SB, Hudson DV, Lichtiger B, Rubenstein EB. Costs of blood transfusion: a process-flow analysis. Journal of Clinical Oncology. 1998;16:2364–2370
  32. Crémieux PY, Barrett B, Anderson K, Slavin MB. Cost of outpatient blood transfusion in cancer patients. Journal of Clinical Oncology. 2000;18:2755–2761
  33. Jackson BR, Umlas J, AuBuchon JP. The cost-effectiveness of postoperative recovery of RBCs in preventing transfusion-associated virus transmission after joint arthroplasty. Transfusion. 2000;40:1063–1066
  34. Fergusson D, Hebert PC, Barrington KJ, Shapiro SH. Effectiveness of WBC reduction in neonates: what is the evidence of benefit?. Transfusion. 2002;42:159–165
  35. Wayne AS, Schoenike SE, Pegelow CH. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood. 2000;96:2369–2372
  36. Grimm AM, Flaharty KK, Hopkins LE, et al. Economics of epoetin therapy. Clinical Pharmacy. 1989;8:807–810
  37. Sheingold SH, Churchill DN, Muirhead N, Laupacis A. Recombinant human erythropoietin: factors to consider in cost-benefit analysis. American Journal of Kidney Diseases. 1991;17:86–92
  38. Sheffield R, Sullivan SD, Saltiel E, Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. The Annals of Pharmacotherapy. 1997;31:15–22
  39. Kavanagh BD, Fischer BAI, Segreti EM, et al. Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics. 2001;51:435–441
  40. Etchason J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. The New England Journal of Medicine. 1995;332:719–724
  41. Keating EM, Meding JB, Faris PM, Ritter MA. Predictors of transfusion risk in elective knee surgery. Clinical Orthopaedics. 1998;357:50–59
  42. Shander A. The cost of blood: multidisciplinary consensus conference for a standard methodology. Transfusion Medicine Reviews. 2005;19:66–78
  43. Goodman C, Chan S, Collins P, et al. Ensuring blood safety and availability in the US: technological advances, costs, and challenges to payment–final report. Transfusion. 2003;43:3S–46S
  44. Wallace EL, Churchill WH, Surgenor DM, et al. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion. 1998;38:625–636
  45. Brand A. Immunological aspects of blood transfusions. Blood Reviews. 2000;14:130–144
  46. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood. 1994;84:1703–1721
  47. Pittman DL. Rationale for universal WBC reduction of blood components?. Transfusion. 2000;40:389
  48. Dzik S, AuBuchon J, Jeffries L, et al. Leukocyte reduction of blood components: public policy and new technology. Transfusion Medicine Reviews. 2000;14:34–52
  49. Birkmeyer JD, Goodnough LT, AuBuchon JP, et al. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion. 1993;33:544–551
  50. Combs CA, Murphy EL, Laros RK. Cost-benefit analysis of autologous blood donation in obstetrics. Obstetrics and Gynecology. 1992;80:621–625
  51. Goodnough LT, Bodner MS, Martin JW. Blood transfusion and blood conservation: cost and utilization issues. American Journal of Medical Quality. 1994;9:172–183
  52. Duffy G, Tolley K. Cost analysis of autologous blood transfusion, using cell salvage, compared with allogeneic blood transfusion. Transfusion Medicine (Oxford, England). 1997;7:189–196
  53. Blumberg N, Heal JM. Immunomodulation by blood transfusion: an evolving scientific and clinical challenge. The American Journal of Medicine. 1996;101:299–308
  54. Roddie PH, Turner ML, Williamson LM. Leucocyte depletion of blood components. Blood Reviews. 2000;14:145–156
  55. van de Watering LMG, Hermans J, Houbiers JGA, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation. 1998;97:562–568
  56. van de Watering LMG, Brand A, Houbiers JGA, et al. Perioperative blood transfusions, with or without allogeneic leucocytes, relate to survival, not to cancer recurrence. The British Journal of Surgery. 2001;88:267–272
  57. Pruss A, Kalus U, Radtke H, et al. Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions. Transfusion and Apheresis Science. 2004;30:41–46
  58. Fisk JM, Snyder EL. Universal pre-storage leukoreduction – a defensible use of hospital resources: the Yale-New Haven Hospital experience. Developmental Biology. 2005;120:39–44
  59. Houbiers JGA, van de Watering LMG, Verwey PJM, et al. Leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet. 1994;344:1429–1431
  60. Vamvakas EC. The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. Transfusion. 2000;40:384–386
  61. Thurer RL, Luban NL, AuBuchon JP, et al. Universal WBC reduction. Transfusion. 2000;40:751–752
  62. Jensen LS, Grunnet N, Hanberg-Sorensen F, Jorgensen J. Cost-effectiveness of blood transfusion and white cell reduction in elective colorectal surgery. Transfusion. 1995;35:719–722
  63. Blumberg N, Heal JM, Kirkley SA, et al. Leukodepleted-ABO-identical blood components in the treatment of hematologic malignancies: a cost analysis. American Journal of Hematology. 1995;48:108–115
  64. Purdy FR, Tweeddale MG, Merrick PM. Association of mortality with age of blood transfused in septic ICU patients. Canadian Journal of Anaesthesia. 1997;44:1256–1261
  65. Mynster T, Dybkjaer E, Reimert CM, et al. Prestorage leukofiltration of whole blood and SAGM blood prevents extracellular bioactive substance accumulation. Inflammation Research. 1999;48:363–368
  66. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA: The Journal of the American Medical Association. 1993;269:3024–3029
  67. Offner PJ, Moore EE, Biffl WL, et al. Increased rate of infection associated with transfusion of old blood after severe injury. Archives of Surgery. 2002;137:711–717
  68. Vamvakas EC, Carven JH. Transfusion and postoperative pneumonia in coronary artery bypass graft surgery: effect of the length of storage of transfused red cells. Transfusion. 1999;39:701–710
  69. National Blood Data Resource Center . Report on blood collection and transfusion in the United States in 1999. http://www.nbdrc.org/research/bloodsurv.htm2002;accessed August 15
  70. Perkins J, Kaminer L, Kruskall M, et al. Should the FDA mandate that autologous units drawn and transfused within a single institution be tested for markers of infectious disease?. Transfusion. 2000;40:752–753
  71. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions . Infectious disease testing for blood transfusions. JAMA: The Journal of the American Medical Association. 1995;274:1374–1379
  72. Food and Drug Administration . Requirements for testing human blood donors for evidence of infection due to communicable disease agents. Final rule. Federal Register. 2001;66:31146–31165
  73. Margolis HS, Coleman PJ, Brown RE, et al. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA: The Journal of the American Medical Association. 1995;274:1201–1208
  74. Busch MP, Dodd RY. NAT and blood safety: what is the paradigm?. Transfusion. 2000;40:1157–1160
  75. Reesink HW, Engelfriet CP, Vrielink H, et al. Consequences of nucleic acid amplification testing for blood transfusion centres. Vox Sanguinis. 1998;74:263–270
  76. Legler TJ, Riggert J, Simson G, et al. Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection. Transfusion. 2000;40:1192–1197
  77. Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion. 2000;40:1165–1168
  78. AuBuchon JP, Birkmeyer JD, Busch MP. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion. 1997;37:45–51
  79. Jackson BR, AuBuchon JP, Busch MP. Cost-effectiveness of nucleic acid testing for HIV and HCV in donated blood. Transfusion. 2000;40(supplement):1385;(abstract)
  80. Pelletier JP, Transue S, Snyder EL. Pathogen inactivation techniques. Best Practice & Research. Clinical Haematology. 2006;19:205–242
  81. AuBuchon JP, Pickard CA, Herschel LH, et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study. Transfusion. 2002;42:146–152
  82. Hambleton J, Viele M, Rios J, et al. RBCs treated with Helinx™ pathogen inactivation have recovery and half-life comparable to conventional RBCs in a randomized crossover trial. In: Proceedings of the 7th Annual Congress of the European Hematology Association. 2002;Florence, Italy
  83. Laupacis A, Fergusson D. Erythropoietin to minimize perioperative blood transfusion: a systematic review of randomized trials. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Transfusion Medicine (Oxford, England). 1998;8:309–317
  84. Titlestad K, Kristensen T, Jorgensen J, Georgsen J. Monitoring transfusion practice - a computerized procedure. Transfusion Medicine (Oxford, England). 2002;12:25–34
  85. Jensen NJ, Crosson JT. An automated system for bedside verification of the match between patient identification and blood unit identification. Transfusion. 1996;36:216–221
  86. Sherwood WC, Bauman ET, Glenn T. The use of computers in the blood bank to reduce transfusion risk. In:  Nance ST editors. Blood supply. Risks, perceptions and prospects for the future. 1st edn. Bethesda, MD: American Association of Blood Banks; 1994;p. 25–43
  87. AuBuchon JP, Littenberg B. A cost-effectiveness analysis of the use of a mechanical barrier system to reduce the risk of mistransfusion. Transfusion. 1996;36:222–226
  88. Sazama K. Current good manufacturing practices for transfusion medicine. Transfusion Medicine Reviews. 1996;X:286–295
  89. Callum JL, Pinkerton PH, Coovadia AS, et al. An evaluation of the process and costs associated with targeted lookbacks for HCV and general notification of transfusion recipients. Transfusion. 2000;40:1169–1175
  90. McCarthy BD, Wong JB, Munoz A, Sonnenberg FA. Who should be screened for HIV infection? A cost-effectiveness analysis. Archives of Internal Medicine. 1993;153:1107–1116
  91. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA: The Journal of the American Medical Association. 1993;270:474–478
  92. Sonnenberg FA, Gregory P, Yomtovian R, et al. The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. Transfusion. 1999;39:808–817
  93. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Annals of Internal Medicine. 1995;122:664–675
  94. Carson JL, Altman DG, Duff A, et al. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion. 1999;39:694–700
  95. Dickie H, Vedio A, Dundas R, et al. Relationship between TISS and ICU cost. Intensive Care Medicine. 1998;24:1009–1017
  96. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. The New England Journal of Medicine. 1996;334:1685–1690
  97. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion. 1990;30:583–590
  98. Sazama K. Bacteria in blood for transfusion: a review. Archives of Pathology & Laboratory Medicine. 1994;118:350–365
  99. Papia G, McLellan BA, El Helou P, et al. Infection in hospitalized trauma patients: incidence, risk factors, and complications. The Journal of Trauma. 1999;47:923–927
  100. Vrielink H, Reesink HW. Transfusion-transmissible infections. Current Opinion in Hematology. 1998;5:396–405
  101. Fransen E, Maessen J, Dentener M, et al. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest. 1999;116:1233–1239
  102. Claas FHJ, Roelen DL, van Rood JJ, Brand A. Modulation of the alloimmune response by blood transfusions. Transfusion Clinique et Biologique. 2001;8:315–317
  103. Hull RJ, Bray RA, Hillyer C, Swerlick RA. Transfusion-associated chronic cutaneous graft-versus-host disease. Journal of the American Academy of Dermatology. 1995;33:327–332
  104. Silliman CC. Transfusion-related acute lung injury. Transfusion Medicine Reviews. 1999;13:177–186
  105. Hebert PC. Disclosure of adverse events and errors in healthcare: an ethical perspective. Drug Safety. 2001;24:1095–1104
  106. Liu JW, Su YK, Liu CF, Chen JB. Nosocomial blood-stream infection in patients with end-stage renal disease: excess length of hospital stay, extra cost and attributable mortality. The Journal of Hospital Infection. 2002;50:224–227
  107. Orsi GB, Di Stefano L, Noah N. Hospital-acquired, laboratory-confirmed bloodstream infection: increased hospital stay and direct costs. Infection Control and Hospital Epidemiology. 2002;23:190–197
  108. Letarte J, Longo CJ, Pelletier J, et al. Patient characteristics and costs of severe sepsis and septic shock in Quebec. Journal of Critical Care. 2002;17:39–49
  109. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine. 2001;29:1303–1310
  110. Sazama K. Legal aspects of transfusion medicine. MLO: Medical Laboratory Observer. 1994;26:33–40
  111. Sullivan P. Developing an administrative plan for transfusion medicine–a global perspective. Transfusion. 2005;45:224S–240S
  112. Asadi MJ, Baltz WA. Activity-based costing for clinical paths. An example to improve clinical cost & efficiency. Journal of the Society for Health Systems. 1996;5:1–7
  113. Shander A, Goodnough LT. Objectives and limitations of bloodless medical care. Current Opinion in Hematology 2006; 13:462–470.
  114. Monk TG, Goodnough LT, Birkmeyer JD, et al. Acute normovolemic hemodilution is a cost-effective alternative to preoperative autologous blood donation by patients undergoing radical retropubic prostatectomy. Transfusion. 1995;35:559–565
  115. Pereira A. Cost-effectiveness analysis and the selection of blood products. Current Opinion in Hematology. 2000;7:420–425
  116. Chernow B. Blood conservation in critical care–the evidence accumulates. Critical Care Medicine. 1993;21:481–482
  117. Goodnough LT, Verbrugge D, Marcus RE. The relationship between hematocrit, blood lost, and blood transfused in total knee replacement. Implications for postoperative blood salvage and reinfusion. The American Journal of Knee Surgery. 1995;8:83–87
  118. Keating EM, Ritter MA. Transfusion options in total joint arthroplasty. The Journal of Arthroplasty. 2002;17:125–128
  119. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology. 2001;19:2865–2874
  120. Crawford J, Demetri GD, Gabrilove JL, et al. Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clinical Lung Cancer. 2002;3:180–190
  121. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Journal of Clinical Oncology. 1998;16:3412–3425
  122. Gabrilove JL, Einhorn LH, Livingston RB, et al. Once-weekly dosing of epoetin-alfa is similar to three-times-weekly dosing in increasing hemoglobin and quality of life. Proceedings American Society of Clinical Oncology. 1999;18:574a;(abstract 2216)
  123. Glaspy J, Degos L, Dicato M, Demetri GD. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist. 2002;7:126–135
  124. Frankenfield DL, Johnson CA. Current management of anemia in adult hemodialysis patients with end-stage renal disease. American Journal of Health-system Pharmacy. 2002;59:429–435
  125. MacLaren R, Sullivan PW. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. Value Health. 2005;8:105–116

PII: S1521-6896(07)00006-7

doi: 10.1016/j.bpa.2007.01.002

Best Practice & Research Clinical Anaesthesiology
Volume 21, Issue 2 , Pages 271-289 , June 2007

Article Tools

* Image Usage & Resolution